Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ASH 2024

Lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Lymphoma

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Haematologica

Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC

doi: 10.3324/haematol.2024.285977

Lymphoma

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy

Am J Hematol

Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC

doi: 10.1002/ajh.27283

Lymphoma

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Leuk Lymphoma

Crombie JL, Jun M, Wang T, Mutebi A, Wang A, Chhibber A, Kamalakar R, Ukropec J, Blaedel J, Kalsekar A

doi: 10.1080/10428194.2024.2371472

Lymphoma

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis

Haematologica

Tolley ER, Lewinter C, Pedersen LM, Nielsen TH

doi: 10.3324/haematol.2023.284281

SPECIAL REPORT

Lymphoma

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Blood Cancer J

Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L

doi: 10.1038/s41408-024-01195-4

Related content

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL